statement
LG Chem signed a revised license agreement with Rhythm Pharmaceuticals for Bivamelagon on November 3, expanding total contract value from $305 million to $855 million.
A statement by LG화학. Statements are as reported by the cited publishers — not verified by DecisionGateway.
11월 3일 리듬 파마슈티컬스와 비바멜라곤(Bivamelagon) 라이선스 계약 개정 체결.
More claims by LG화학
LG Chem expects the Tennessee cathode plant to begin full-scale mass production from 1Q27, considering Ultium Cells' inventory and production plans, and aims to agree on mid-to-long-term supply volumes and compensation within the year.predictionLG Chem expects petrochemical oversupply to continue in 2027 despite some global plant closures, and projects about 29 million tons of new capacity additions versus about 8 million tons of closures in Northeast Asia through 2031.predictionLG Chem decided to use about 20% of after-tax cash proceeds from LG Energy Solution stake sale for shareholder returns, judging its share price significantly undervalued versus intrinsic value.commitmentLG Chem will exclude low-density LFP from initial commercialization and focus on high-density LFP with differentiated technology and supply chain, targeting about 40,000 tons of supply contracts as high-density LFP demand ramps up in 2028-2029.commitmentLG Chem expects 2027 cathode material shipments to more than double versus 2026, driven by expanded supply from projects that began shipping in 3Q this year and full-year reflection.prediction
All claims by LG화학